10x Genomics develops instruments, consumables, and software for analyzing biological systems. Their Chromium platforms enable single-cell gene expression and multi-omics, while Visium and the new Atera platform offer advanced spatial biology insights, including whole transcriptome profiling. They serve academic, government, and biopharma researchers, with AI-driven demand increasing.
Key Inputs And Sourcing
1. Reagents / Biochemical Materials
Not in registry
component · Global, Singapore · unknown
Source Explicitly mentioned as critical for consumables and kits (e.g., 'reagent kits', 'proprietary chemistry', 'enzymes, oligonucleotides, primers, probes, buffers, and other assay reagents'). Manufacturing facility in Singapore for reagents.
Confidence: high
2. Microfluidic Chips / Slides / Plastic Consumables
Not in registry
component · Global · unknown
Source Essential for single-cell and spatial platforms (e.g., 'microfluidic chips', 'custom chips, cartridges, slides, and molded parts').
Confidence: high
3. Instrument Components (Electronics, Optics, Precision Assemblies)
Not in registry
component · Global · unknown
Source Critical for manufacturing Chromium, Xenium, and Atera instruments (e.g., 'Optics, imaging parts, electronics, precision assemblies, and other specialized hardware').
Confidence: high
4. Manufacturing Labor
Not in registry
labor · US, Singapore · unknown
Source Implied by 'lower manufacturing costs' and operation of manufacturing facilities.
Confidence: high
5. Logistics and Cold-Chain Services
Not in registry
logistics · containerized-freight-index · Global · unknown
Source 'Logistics and cold-chain providers: Some reagents and kits require careful storage and shipping conditions.'
Confidence: medium
6. Gel Beads
Not in registryaccess=api
component · Global · unknown
Source Core component of GEM technology, containing barcoded primers.
Confidence: high
7. Software Development Labor
Not in registry
labor · Global · unknown
Source 'Bioinformatics expertise required to analyze increasingly rich data sets', 'software side' for Atera, 'computational biology, software' as distinctive capabilities.
Confidence: high
8. Packaging Materials
Not in registry
packaging · Global · unknown
Source Procured from qualified suppliers.
Confidence: medium
9. Partitioning Oil
Not in registry
component · Global · unknown
Source Used in microfluidic process to create GEMs.
Confidence: medium
Industry Publications
- GenEngNews (GEN) (genengnews.com) — Essential for tracking broader trends in genetic engineering, biotechnology, and 'omics' technologies, including new product launches and research advancements relevant to 10x Genomics' platforms. [cite: Theme_Overview]
- Nature Biotechnology (nature.com/nbt) — A leading journal for high-impact research in biotechnology, frequently publishing advancements in single-cell and spatial biology, directly relevant to 10x Genomics' core technologies.
- Cell (cell.com) — A top-tier scientific journal that publishes groundbreaking research in cell biology, often featuring studies utilizing advanced single-cell and spatial analysis techniques.
- Briefings in Bioinformatics (academic.oup.com/bib) — Important for monitoring advancements in bioinformatics and computational biology, which are critical for analyzing the large datasets generated by 10x Genomics' platforms, especially with the rise of AI in biology.
- BioProcess International (bioprocessintl.com) — Premier publication tracking cell culture media, downstream chromatography purification consumables, and single-use reagents from early research to biomanufacturing scale, relevant to the consumables aspect of 10x Genomics' business. [cite: Theme_Overview]
Economic Data Watch
1. PitchBook-NVCA Venture Monitor — Venture Capital Funding Data
Not in registry
Metric/field Global Biotech Venture Capital Funding (USD Billions)
Cadence quarterly
Why it matters Higher funding signals increased R&D spending by early-stage biotechs, driving demand for life science tools and services, directly impacting TXG's customer base.
Signal to watch Upward trend
Confidence: high
2. National Institutes of Health (NIH) — NIH Awards by Institute and Center / NIH RePORTER
Not in registry
Metric/field Total NIH Research Project Grants (RPGs) Funding (USD)
Cadence annual
Why it matters Direct indicator of academic research funding, which drives demand for 10x Genomics' tools in universities and academic medical centers, as government funding is a key priority.
Signal to watch Upward trend
Confidence: high
3. BEA — National Income and Product Accounts (NIPA)
Not in registryaccess=api
Metric/field A191RL1Q225SBEA
Cadence quarterly
Why it matters Broader economic health in the U.S. (Americas revenue up 6%) influences R&D budgets and overall spending capacity of customers, including biopharma and academic institutions.
Signal to watch Higher growth
Confidence: high
4. Trading Economics — China Economic Indicators
Not in registryaccess=scrape
Metric/field China Industrial Production
Cadence monthly
Why it matters Reflects economic health and manufacturing activity in China, a key APAC market where revenue was down 19% due to prior year pull-forward, influencing R&D spending capacity.
Signal to watch Higher growth
Confidence: high
5. Trading Economics — Euro Area Economic Indicators
Not in registryaccess=scrape
Metric/field Euro Area GDP Growth
Cadence quarterly
Why it matters Reflects economic health in the EMEA region, which grew 15%, indicating strong performance and influencing R&D budgets for 10x Genomics' customers.
Signal to watch Higher growth
Confidence: high
Free Alt Data Watch
1. ClinicalTrials.gov — Study Records
Not in registry
Metric/field Number of new studies initiated (status 'Not yet recruiting' or 'Recruiting') for 'single-cell' OR 'spatial biology' OR '10x Genomics' OR 'Atera' OR 'Chromium' OR 'Xenium' OR 'Visium' OR 'Flex Apex'
Cadence daily
Why it matters Indicates the expanding pipeline and R&D activity in key therapeutic areas and technologies relevant to 10x Genomics, such as oncology, neurodegeneration, and cell therapies, which drives demand for their platforms.
Signal to watch Increasing number of studies
Confidence: high
2. USASpending.gov — Federal Contract and Grant Awards
Not in registryaccess=api
Metric/field Total award amount (USD) to academic/research institutions or biopharma companies for 'single-cell' OR 'spatial biology' OR 'genomics' OR 'AI biology'
Cadence daily
Why it matters Tracks government funding flowing into research areas that directly utilize or benefit from 10x Genomics' technologies, reflecting 'philanthropic and government funding priorities'.
Signal to watch Increasing award amounts
Confidence: medium
3. Google Trends — Search Interest Data
Not in registry
Metric/field Search interest for '10x Genomics' OR 'Atera' OR 'single-cell sequencing' OR 'spatial transcriptomics'
Cadence daily
Why it matters Provides a proxy for general market awareness and interest in 10x Genomics' company, new products like Atera, and core technologies, influencing future demand.
Signal to watch Increasing search interest
Confidence: high
4. SEC EDGAR — Company Filings (10-K, 10-Q, 8-K)
Matched (medium)alphasense_company_filings_transcripts_research · access=file · map_only
Metric/field Mentions of '10x Genomics' OR 'single-cell' OR 'spatial biology' OR 'Atera' in filings of biopharma companies or research institutions (e.g., CIKs of major customers/partners)
Cadence daily
Why it matters Indicates adoption, partnerships, or strategic investments by customers and competitors in technologies relevant to 10x Genomics, reflecting market traction and competitive landscape.
Signal to watch Increasing mentions or positive context
Confidence: medium
5. Indeed Hiring Lab — Job Postings Data
Not in registry
Metric/field Number of job postings containing 'single-cell' OR 'spatial biology' OR 'genomics' OR 'AI biology' OR '10x Genomics' by biopharma/academic employers
Cadence monthly
Why it matters Reflects R&D expansion and investment in areas leveraging 10x Genomics' technologies, indicating underlying demand for skilled personnel to utilize these platforms.
Signal to watch Increasing job postings
Confidence: medium
Paid Alt Data Watch
1. IQVIA — Medical Claims Data
Matchediqvia_medical_claims · access=file · map_only
Metric/field CPT code utilization for molecular diagnostic tests (e.g., specific codes for liquid biopsy, MRD, MCED, CGP, Alzheimer's biomarkers) that rely on NGS/spatial technologies
Cadence monthly
Why it matters Directly tracks the adoption and utilization of molecular diagnostic tests, aligning with 10x Genomics' future vision to extend technologies into clinical diagnostics and generate robust clinical evidence.
Signal to watch Increasing utilization
Confidence: high
2. YipitData — Medtech Product (Hospital/Surgical Center Purchasing)
Matchedyipitdata_hospital_purchasing_medtech_procurement · access=file · map_only
Metric/field Purchasing volume/spend for '10x Genomics' products (e.g., Chromium, Xenium, Atera consumables, instruments) by hospitals/research centers
Cadence monthly
Why it matters Provides direct insight into the sales and adoption of 10x Genomics' instruments and consumables by its core customer base, reflecting actual demand and utilization.
Signal to watch Increasing purchasing volume/spend
Confidence: high
3. Similarweb — Web Traffic & Engagement Data
Matchedsimilarweb_website_traffic_engagement · access=file · map_only
Metric/field Website traffic (unique visitors, page views) to 10xgenomics.com and key competitor websites, or specific product pages (e.g., Atera, Chromium)
Cadence monthly
Why it matters Serves as a leading indicator of customer interest, engagement, and research activity related to 10x Genomics' offerings and the broader market.
Signal to watch Increasing traffic and engagement
Confidence: high
4. Clarivate Life Sciences & Healthcare — Market Research Reports / Industry Intelligence
Matchedclarivate_life_sciences_drug_intelligence · access=file · map_only
Metric/field Market size and growth forecasts for single-cell analysis, spatial biology, and genomics tools and reagents (e.g., specific segments like 'spatial transcriptomics market')
Cadence irregular
Why it matters Provides strategic insights into the overall market trajectory for 10x Genomics' core businesses and future growth opportunities, validating their market expansion claims.
Signal to watch Upward revisions to market forecasts
Confidence: high
5. Hatched Analytics — Ticker-level KPI Feeds
Matchedhatched_analytics_ticker_level_transaction_digital_kpi_feeds · access=file · map_only
Metric/field Key Performance Indicators (KPIs) derived from proprietary transaction data for TXG or its major biopharma/academic customers, related to lab spending or research activity
Cadence monthly
Why it matters Offers granular, real-time insights into the operational performance and customer spending patterns that directly impact 10x Genomics' revenue.
Signal to watch Positive KPI trends
Confidence: medium
Search Keywords Brand Product
- Atera platform
- Chromium instruments
- Visium spatial gene expression
- Xenium spatial analysis
- Flex Apex
- Multiome product
- Catalyst Research Services
- Proteintech Genomics
- single-cell analysis
- spatial biology
- multi-omics
- AI drug discovery
- genomic research tools
- life science technology
- proteomics
Search Keywords Event Phrases
- 10x Genomics earnings
- Atera launch
- Proteintech Genomics acquisition
Search Keywords Policy Regulatory
- academic research budget caps
- NIH research grant outlays
- What They Do (Plain English & Analogies)
- 10x Genomics creates advanced tools, including specialized instruments, chemical kits, and software, that help scientists study biological samples at an incredibly detailed level. Imagine trying to understand a bustling city. Instead of just seeing a map, 10x Genomics' technology allows researchers to zoom in and see what every individual person (cell) is doing, where they are located within a neighborhood (tissue), and how they interact. This 'zoom-in' capability, known as single-cell and spatial analysis, provides a much clearer picture of how diseases like cancer or Alzheimer's develop, and helps in finding new ways to treat them. Their newest platform, Atera, is like an even more powerful, high-resolution camera that can capture even more information across a larger area.
- Very Brief History
- Founded in 2012, initially as 10X Technologies, Inc., and later rebranded to 10x Genomics, Inc. in November 2014, the company is headquartered in Pleasanton, California. It quickly established itself as a leader in life science technology, pioneering single-cell analysis with its Chromium platforms. The company then expanded into spatial analysis with Visium and Xenium, and most recently launched its advanced Atera platform, further solidifying its position in cutting-edge biological research.
- "Street Stereotype"
- 10x Genomics is generally perceived as a leading innovator in the life science tools sector, particularly in the rapidly evolving fields of single-cell and spatial biology. Investors and analysts often view it as a high-growth company with a strong pipeline of transformative technologies, such as the recently launched Atera platform, which is expected to drive significant market expansion. However, the market also closely scrutinizes the company's ability to manage the transition from older products to new ones, scale manufacturing for complex instruments, and translate strong demand into tangible revenue amidst broader macroeconomic uncertainties and academic funding constraints.
- Subsidiaries On Linked In*
- Proteintech Genomics — Acquired by 10x Genomics in June 2026 to expand proteomics capabilities. Previously a division within Proteintech Group.; LinkedIn: Proteintech Genomics
- Customer Sectors & Example Clients
- 10x Genomics serves a diverse range of customers across various sectors. These include academic institutions, governmental organizations, biopharmaceutical companies, biotechnology companies, and academic medical centers. Specific examples of clients or partners mentioned include the Cleveland Clinic and Lausanne University Hospital, with whom 10x Genomics has partnerships to identify biomarkers in oncology. The company also engages with top biopharmaceutical companies and academic initiatives like CZI and the Arc Institute, which are focused on building virtual biology models.
- New Customers / Segments They'Re Targeting
- 10x Genomics is actively targeting new customer segments beyond early technology adopters. They are focusing on expanding their reach within biopharma companies and academic medical centers for integrating their platforms into routine research, such as translational oncology programs. The company is also making its Atera platform accessible to researchers who may not yet own an instrument through its Catalyst Research Services, allowing them to submit samples for processing in 10x Genomics' labs. Furthermore, 10x Genomics envisions a significant long-term opportunity to extend its technologies into clinical diagnostics, particularly in oncology and autoimmunity, by generating robust clinical evidence on large patient cohorts. A key target segment also includes the rapidly growing number of biotech companies and large academic projects focused on building sophisticated virtual models of human biology using AI.
- Sales Geographies And Expansion Plans
- 10x Genomics currently sells its products globally across several key geographies. These include the Americas, Europe, the Middle East, Africa (EMEA), China, and the broader Asia Pacific (APAC) region. Specific Asian locations mentioned include Jui Bei City, Taiwan; Shanghai, China; Singapore; and Tokyo, Japan. While the company has not disclosed specific plans to expand into entirely new geographic regions, its strategy focuses on deepening engagement within its existing markets and expanding the application of its technologies across these regions.
- How Key Themes May Help/Hurt
- 10x Genomics is well-positioned to benefit significantly from the 'Life Sciences '24: Research Reagents & Consumables' theme. The growth in proteomics, immunology, cell biology, and drug-discovery experimentation directly expands demand for the specialized reagents and consumables integral to 10x Genomics' single-cell and spatial platforms. [cite: Theme_BullBearDetails, 1] The expansion of single-cell analysis and spatial biology, core to TXG's offerings, will increase the consumption of their proprietary sample-preparation kits and reagents. [cite: Theme_BullBearDetails, 2] The recurring nature of laboratory purchasing and the increasing throughput of experiments driven by automation will lead to sustained demand for their high-margin consumables. [cite: Theme_BullBearDetails, 3] Furthermore, the convergence of AI drug discovery with high-throughput wet-lab validation will accelerate demand for the vast amounts of experimental data generated by 10x Genomics' technologies. [cite: Theme_Overview, 10] Conversely, the company could be hurt by reduced biotechnology funding, pharmaceutical research budget cuts, or weaker academic grants, which could decrease overall experimental activity and purchasing, especially for expensive specialty reagents and exploratory research programs. [cite: Theme_BullBearDetails, 1] Competition from alternative assay methods or other suppliers could also pressure pricing and customer retention. [cite: Theme_BullBearDetails, 2] Lastly, issues such as reagent inconsistency, supply shortages, or poor experimental reproducibility could disrupt research workflows and damage supplier relationships. [cite: Theme_BullBearDetails, 3]
3 Main Long-Term Bull Details
- Pioneering and Leading Spatial Biology with Atera: The launch of Atera, described as a "game-changing new platform," is poised to transform biological research by enabling spatial whole transcriptome profiling with single-cell sensitivity at scale. This platform is expected to amplify and accelerate the growth of the spatial market, with an extensive roadmap including workflow automation, base-by-base spatial sequencing, and protein multi-omics, ensuring long-term innovation and market leadership.
- Structural Tailwinds from AI in Biology: AI is identified as a "significant and structural tailwind" for 10x Genomics. The company's single-cell and spatial technologies are uniquely positioned to provide the high-quality, high-resolution biological data essential for training AI models, which are increasingly pervasive across academic and biopharma research for target identification and drug development.
- Strong Multi-omics and Consumables Growth: 10x Genomics continues to drive robust growth in its consumables business, particularly with the accelerating momentum of Flex Apex in single-cell and Xenium in spatial. The company's focus on multi-omics, enhanced by the acquisition of Proteintech Genomics, provides comprehensive solutions for measuring gene expression and proteins on the same cell, catering to a growing interest in additional modalities and expanding usage across a broad range of applications.
3 Main Long-Term Bear Details
- Macroeconomic Headwinds and Funding Constraints: The academic funding environment remains "tenuous," with grant approvals not fully translating into purchasing activity, and persistent issues like increased oversight and staffing shortages affecting spending decisions. This challenging macro environment could continue to dampen demand for expensive instruments and consumables, impacting revenue growth.
- Transition Dynamics and Cannibalization Risk: The introduction of new, advanced platforms like Atera creates "transition dynamics," where customers moderate purchases of existing spatial products (Xenium and Visium) in anticipation of the new technology. While Atera is expected to ultimately drive market expansion, the timing and extent of this cannibalization could create near-to-medium term revenue fluctuations and impact the adoption rate of older platforms.
- Manufacturing and Scaling Challenges for New Products: Despite "extraordinary" demand for Atera, the company faces "manufacturing capacity constraints" in the near term, limiting the number of units that can be shipped. The ability to rapidly scale production for a complex, game-changing platform like Atera will be critical, and any delays or difficulties in this process could impact revenue recognition and market expectations for the platform's rollout.
- Competitors And Differentiation
- While specific competitors are not explicitly named in the transcript, 10x Genomics operates in the competitive single-cell and spatial biology markets. The company differentiates itself through several key aspects: its platforms deliver the highest data quality, largest scale, widest biological context, and most powerful multi-omics capabilities. The recently launched Atera platform is highlighted as a 'game-changing new platform' that provides 'step change advances' in throughput, flexibility, and sensitivity, enabling spatial whole transcriptome profiling with single-cell sensitivity at scale. The acquisition of Proteintech Genomics further strengthens its multi-omics offerings by integrating rich proteomic information alongside spatial transcriptomics. 10x Genomics also emphasizes its crucial role in enabling AI-driven biological research, positioning its tools as foundational for training high-quality, generalizable AI models.
- Recent Performance & What The Market'S Focused On
- In the second quarter of 2026, 10x Genomics reported revenue of $151 million, or $149.4 million excluding non-recurring settlement revenue, representing a 3% year-over-year growth on an adjusted basis. Total consumables revenue increased by 7%, driven by 3% growth in single-cell consumables and 16% growth in spatial consumables, with Xenium being the primary driver. Conversely, total instrument revenue declined by 47%, with both Chromium and spatial instrument revenues falling by 46% and 48% respectively, largely due to customers moderating purchases in anticipation of the Atera launch. Gross margin improved to 74% (excluding non-recurring items). The company raised its full-year 2026 revenue outlook to $610-$630 million. The market is intensely focused on the "extraordinary customer response" and strong early order flow for the new Atera platform, particularly its demand exceeding initial shipment expectations. Key areas of market scrutiny include the company's ability to ramp up Atera manufacturing and shipments (with 40 units expected in Q4), the ongoing transition dynamics impacting existing spatial products, the growth trajectory of Flex Apex in single-cell, and the tangible revenue impact of AI-driven demand.
- Revenue Segments And Estimated Mix
- Consumables — Mix: ~96%; Source: Q2 2026 transcript, calculated from adjusted revenue; Trend: Grew 7% YoY; Single-cell consumables grew 3% YoY, Spatial consumables grew 16% YoY with Xenium as primary driver.
- Instruments — Mix: ~4%; Source: Q2 2026 transcript, calculated from adjusted revenue; Trend: Declined 47% YoY; Chromium instruments declined 46% YoY, Spatial instruments declined 48% YoY due to anticipation of Atera.
- License and Royalty Revenue — Mix: n/m; Source: Q2 2026 transcript; Trend: $1.6 million in Q2 2026, non-recurring settlement revenue.
- Product Brands
- Chromium
- Chromium Connect
- Visium
- Xenium
- Atera
- Flex Apex
- Multiome
- GEM-X
- Catalyst Research Services
- Proteintech Genomics Human Discovery Panel